Income statement
USD
Annual
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 16M | 14M | 19M | 16M | 11M |
| Gross Profit | 9M | 6M | 9M | 9M | 5M |
| Operating Income | -321K | -3M | -5M | -341K | -6M |
| EBITDA | 382K | -2M | 3M | 87K | -6M |
| Net Income | 239K | -3M | -11M | -273K | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.648
+3.35% today
1Y Change
-98.33%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zhongchao Inc. (ZCMD) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.65 and down 98.3% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of -28.3%, EPS growth of -92.7%, a dividend yield of 0.0%. What stands out right now is revenue -28.3%, EPS -92.7%, free cash flow +115.3% with operating margin -54.4% and ROIC -27.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZCMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZCMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZCMD Max Drawdown
-98.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZCMD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$11.4M
-28.3% YoY
FY Net Income
-$5.8M
-2026.8% YoY
Free Cash Flow
$692.8K
+115.3% YoY
Revenue Growth
-28.3%
EPS Growth
-92.7%
Gross Margin
43.8%
Net Margin
-55.5%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 16M | 14M | 19M | 16M | 11M |
| Gross Profit | 9M | 6M | 9M | 9M | 5M |
| Operating Income | -321K | -3M | -5M | -341K | -6M |
| EBITDA | 382K | -2M | 3M | 87K | -6M |
| Net Income | 239K | -3M | -11M | -273K | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14M | 12M | 8M | 8M | 8M |
| Total Assets | 36M | 39M | 24M | 26M | 24M |
| Total Liabilities | 4M | 6M | 3M | 2M | 2M |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 202K | 2M | 808K | 58K | 26K |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
145K
+94.5% YoY
Capital Expenditures
—
Free Cash Flow
693K
+115.3% YoY
Key ratios
Gross Margin
43.8%
Operating Margin
-54.4%
Net Margin
-55.5%
ROE
-32.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.